knowledge -WSS

knowledge

author：explore 2025-10-01 04:12:05 - browse：713

Brain cancer — Michelle Monje/Stanford University/NIH

Tocagen (TOCA) said Tuesday that a Phase 3 clinical trial involving a novel gene therapy for aggressive brain tumors will continue to a final analysis later this year, following an interim look at patient survival data conducted by independent monitors. Tocagen’s stock price dropped sharply.

The San Diego-based biotech pitched the study’s continuation as an encouraging sign for its gene therapy called Toca 511/Toca FC, which is designed to deliver a localized chemotherapy directly to the site of brain tumors.

“We believe the longer-term follow-up of patients in the final analysis, particularly for those randomized in the second enrollment period, will be important in assessing both primary and secondary endpoints,” said Tocagen CEO Marty Duvall, in a statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： The dental labor crisis is a moment of opportunity

focus

WSS

DeSantis can now import cheaper drugs. But will Biden get credit?

How I ended up pumping milk in a bathroom stall at JPM 2024

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Medicare Advantage proposed rates disappoint insurers

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Medical mystery: When a cough is not just a cough

knowledge

knowledge

leisure time

The high cost of giving birth even with insurance

KalVista pill reduced swelling 'attacks' caused by genetic disease

Medical records are filled with copy

HHS names first

Guidelines to prevent youth baseball injuries need more muscle

BioAge raises $170M for combination therapy with Zepbound

ChatGPT in medicine: STAT answers readers' burning questions

Vaccine advisory panel ACIP left half staffed by HHS

Medicare proposal to cover medical devices draws a mixed reaction

How digital tools helped lower hypertension in marginalized patients

leisure time

What we’ve learned from the Aduhelm mess

JPM 2024: Verve Therapeutics looks to mainstream genome editing

Medicare Advantage proposed rates disappoint insurers

New menopause drug shows promise in relief for hot flashes

Senators start work on Medicare physician payment reform

New England Journal of Medicine addresses racist history, slavery

focus

focus

focus

knowledge